- Home
- SQFT vs MBIO Comparison
SQFT vs MBIO Comparison
Compare SQFT & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SQFT | MBIO |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9M | 4.7M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | SQFT | MBIO |
|---|---|---|
| Price | $3.20 | $1.12 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 82.7K | ★ 102.8K |
| Earning Date | 11-12-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $17,525,365.00 | N/A |
| Revenue This Year | $23.63 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.04 | $0.89 |
| 52 Week High | $23.00 | $21.95 |
Technical Indicators
Market Signals| Indicator | SQFT | MBIO |
|---|---|---|
| Relative Strength Index (RSI) | 28.99 | 37.70 |
| Support Level | $3.83 | $1.06 |
| Resistance Level | $4.80 | $1.31 |
| Average True Range (ATR) | 0.34 | 0.09 |
| MACD | -0.03 | -0.01 |
| Stochastic Oscillator | 10.50 | 8.11 |
Price Performance
Historical ComparisonAbout SQFT Presidio Property Trust Inc.
Presidio Property Trust Inc is an internally managed, diversified REIT with holdings in model home properties which are triple-net leased to homebuilders, office, industrial, and retail properties. Presidio's model homes are leased to homebuilders located in Arizona, Illinois, Texas, Wisconsin, and Florida. The office, industrial and retail properties are located in Colorado, with properties also located in Maryland, North Dakota, Texas, and Southern California.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.